Zacks Investment Research on MSN
ETFs to buy post JNJ's Q2 earnings beat & bullish 2026 outlook
Medtech giant Johnson & Johnson JNJ reported better-than-expected second-quarter 2026 results, surpassing Wall Street estimates on both the top and bottom lines. The quarterly performance was ...
Zacks Investment Research on MSN
Johnson & Johnson (JNJ) is attracting investor attention: Here is what you should know
Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are ...
Both Johnson and Johnson and Coca-Cola just beat earnings and both are pulling in capital fleeing tech, but only one of them earns its premium valuation in a world where pricing tailwinds can reverse ...
Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by ...
JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results